AI drug development company
Pathos AI
Pathos AI is a New York clinical-stage AI and technology company that develops its own drugs. Its Foundry platform runs thousands of AI agents to estimate the probability of success of clinical programs and guide trials. Its pipeline covers cancers such as prostate cancer and multiple myeloma. It raised a $237 million Series E in October 2026.
Last reviewed 28 Oct 2026
Facts at a glance
| Type | Clinical-stage AI drug development company |
|---|---|
| Headquarters | New York City source |
| Latest round | $237 million Series E at a post-money valuation of approximately $3 billion, 23 October 2026 source |
| Lead investor | Bristol Myers Squibb source |
| Clinical assets | Four active clinical assets, including JSKN016, pocenbrodib, AZD4241 and DO-2 source |
| AI platform | Foundry, which runs thousands of specialized AI agents |
| CEO | Iker Huerga |
Questions people ask
- What is Pathos Foundry?
- Pathos's AI platform. The company says it runs thousands of specialized AI agents that combine clinical, genomic and competitive data to pick the next decision for a drug program.
- Who led Pathos AI's Series E?
- Bristol Myers Squibb led the $237 million round, with participation from existing investors.